| 22/05/23 | 07:00:04 | 22 May 2023 | | Unaudited Interim Report |
| 18/05/23 | 07:00:06 | 18 May 2023 | | NXP002 Inflammation and Duration of Action Update |
| 26/04/23 | 10:55:42 | 26 Apr 2023 | | Holding(s) in Company |
| 17/04/23 | 07:00:02 | 17 Apr 2023 | | Subscription to raise £70,000 & issue of Warrants |
| 27/03/23 | 07:00:05 | 27 Mar 2023 | | NXP002 Update |
| 13/03/23 | 07:00:09 | 13 Mar 2023 | | Change of Accounting Reference Date |
| 15/02/23 | 07:00:05 | 15 Feb 2023 | | NXP002 Update |
| 03/01/23 | 13:37:56 | 3 Jan 2023 | | Holding(s) in Company |
| 20/12/22 | 07:00:10 | 20 Dec 2022 | | NXP004 Update |
| 13/12/22 | 07:00:02 | 13 Dec 2022 | | Half-year Report |
| 05/12/22 | 07:00:04 | 5 Dec 2022 | | Resignation of Auditor |
| 16/11/22 | 08:50:23 | 16 Nov 2022 | | Holding(s) in Company |
| 04/11/22 | 07:00:05 | 4 Nov 2022 | | Investor Webinar |
| 23/09/22 | 07:00:06 | 23 Sept 2022 | | NXP002 Update |
| 25/08/22 | 14:39:41 | 25 Aug 2022 | | Result of AGM |
| 19/08/22 | 08:57:47 | 19 Aug 2022 | | Holding(s) in Company |
| 10/08/22 | 07:00:06 | 10 Aug 2022 | | NXP002 Completion of Tolerability Studies |
| 01/08/22 | 12:13:09 | 1 Aug 2022 | | Posting of Annual Report and Notice of AGM |
| 28/07/22 | 07:01:03 | 28 Jul 2022 | | Board Changes |
| 28/07/22 | 07:00:15 | 28 Jul 2022 | | Annual Results for the year ended 31 March 2022 |
| 05/07/22 | 07:00:07 | 5 Jul 2022 | | NXP002 data to be presented at 2022 ERS Congress |
| 29/06/22 | 07:00:05 | 29 Jun 2022 | | NXP004 Update |
| 27/06/22 | 07:00:05 | 27 Jun 2022 | | NXP002 Update |
| 20/06/22 | 07:00:06 | 20 Jun 2022 | | Holding(s) in Company |
| 31/05/22 | 07:00:05 | 31 May 2022 | | Directorate Change |
| 30/05/22 | 07:00:07 | 30 May 2022 | | Corporate Update |
| 12/04/22 | 07:00:03 | 12 Apr 2022 | | Second tranche of Lanstead subscription shares |
| 11/04/22 | 15:54:54 | 11 Apr 2022 | | Holding(s) in Company |
| 08/04/22 | 11:21:12 | 8 Apr 2022 | | Holding(s) in Company |
| 07/04/22 | 15:44:22 | 7 Apr 2022 | | Holding(s) in Company |
| 05/04/22 | 18:07:59 | 5 Apr 2022 | | Holding(s) in Company |
| 28/03/22 | 07:00:07 | 28 Mar 2022 | | NXP004 Patent |
| 02/03/22 | 07:00:08 | 2 Mar 2022 | | Appointment of Dr Dan Gooding as Consultant |
| 01/03/22 | 07:00:11 | 1 Mar 2022 | | Change of Auditor |
| 14/02/22 | 16:37:44 | 14 Feb 2022 | | Holding(s) in Company |
| 08/02/22 | 07:00:05 | 8 Feb 2022 | | Oxilio NXP-001 formulation development contract |
| 01/02/22 | 07:00:05 | 1 Feb 2022 | | Adviser Appointments |
| 31/01/22 | 14:09:26 | 31 Jan 2022 | | Director/PDMR Shareholding |
| 31/01/22 | 11:05:23 | 31 Jan 2022 | | Result of General Meeting |
| 17/01/22 | 09:56:03 | 17 Jan 2022 | | Posting of Circular and Notice of General Meeting |
| 10/01/22 | 16:23:18 | 10 Jan 2022 | | Director/PDMR Shareholding |
| 21/12/21 | 07:00:05 | 21 Dec 2021 | | Holding(s) in Company |
| 14/12/21 | 14:05:59 | 14 Dec 2021 | | Second Price Monitoring Extn |
| 14/12/21 | 14:00:46 | 14 Dec 2021 | | Price Monitoring Extension |
| 14/12/21 | 07:01:09 | 14 Dec 2021 | | Subscription to raise £1.65 million |
| 14/12/21 | 07:00:06 | 14 Dec 2021 | | Half year Report |
| 25/11/21 | 07:00:02 | 25 Nov 2021 | | Positive pre-clinical data on NXP002 |
| 17/11/21 | 09:34:27 | 17 Nov 2021 | | Holding(s) in Company |
| 12/11/21 | 07:00:01 | 12 Nov 2021 | | NXP004 patent application filing |
| 09/11/21 | 07:00:03 | 9 Nov 2021 | | Directorate Change |
